Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG

被引:22
作者
Flux, GD
Guy, MJ
Papavasileiou, P
South, C
Chittenden, SJ
Flower, MA
Meller, ST
机构
[1] Royal Marsden NHS Trust, Dept Phys & Paediat, Sutton SM2 5PT, Surrey, England
[2] Inst Canc Res, Sutton SM2 5PT, Surrey, England
关键词
D O I
10.1089/108497803321269359
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients undergoing targeted radionuclide therapy (TRT) may receive a series of two or more treatment administrations at varying intervals. However, the level of activity administered and the frequency of administration can vary widely from centre to centre for the same therapy. Tumour dosimetry is seldom employed to determine the optimum treatment plan mainly due to the potential inaccuracies of image quanti cation. In this work 3D dose distributions obtained from repeated therapies have been registered to enable the dose ratios to be determined. These ratios are independent of errors in image quantification and, since the same target volume can-be transferred from one distribution to the next, independent of inconsistencies in outlining these volumes. These techniques have initially been applied to ten sets of I-131 mIBG therapy scan data from five patients, each undergoing two therapies. It was found that where a similar level of activity was administered for the second therapy, a similar tumour dose was delivered, and in two cases where a higher level of activity was administered for the second treatment, a correspondingly higher absorbed dose was delivered. This justifies an approach of administering activities based on individual patient kinetics rather than administering standard activities to all patients.
引用
收藏
页码:81 / 87
页数:7
相关论文
共 9 条
[1]  
Clairand I, 1999, J NUCL MED, V40, P1517
[2]   DOSIMETRY OF I-131 METAIODOBENZYLGUANIDINE FOR TREATMENT OF RESISTANT NEUROBLASTOMA - RESULTS OF A UK STUDY [J].
FIELDING, SL ;
FLOWER, MA ;
ACKERY, D ;
KEMSHEAD, JT ;
LASHFORD, LS ;
LEWIS, I .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1991, 18 (05) :308-316
[3]  
GIAP HB, 1995, J NUCL MED, V36, P1885
[4]  
GUY MJ, UNPUB CANC BIOTHER R
[5]  
HOEFNAGEL CA, RADIONUCLIDE THERAPY
[6]  
Kolbert KS, 1997, J NUCL MED, V38, P301
[7]  
Liu A, 1999, J NUCL MED, V40, P1151
[8]  
Matthay KK, 2001, J NUCL MED, V42, P1713
[9]  
Souhami R, 1995, CANC ITS MANAGEMENT